Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR13C9 Inhibitors

OR13C9 inhibitors are a specialized class of chemical compounds designed to target the OR13C9 receptor, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Olfactory receptors, including OR13C9, are primarily involved in detecting odor molecules, which is essential for the sense of smell. However, like many other olfactory receptors, OR13C9 is also expressed in non-olfactory tissues, indicating that it may have additional roles in various physiological processes beyond olfaction. OR13C9 inhibitors work by binding to this receptor and interfering with its ability to interact with natural ligands. This binding can inhibit or modulate the receptor's activity, leading to changes in the signaling pathways it regulates. Research into OR13C9 inhibitors is important for uncovering the broader biological functions of this receptor, particularly in tissues where its role is not fully understood. The chemical nature of OR13C9 inhibitors is diverse, with different compounds exhibiting various mechanisms of action and levels of specificity. Some OR13C9 inhibitors act as competitive antagonists, binding directly to the active site of the receptor and preventing natural ligands from activating it. This direct competition effectively blocks the receptor's normal signaling activity. Other inhibitors may function allosterically, binding to different sites on the receptor and causing conformational changes that reduce its activity or alter its signaling behavior. The development and optimization of OR13C9 inhibitors often involve advanced structural biology techniques such as X-ray crystallography, cryo-electron microscopy, and molecular modeling. These techniques are crucial for identifying key binding sites on the receptor and designing inhibitors that are both potent and selective. Researchers focus on creating inhibitors that specifically target OR13C9 without affecting other GPCRs or unrelated proteins, ensuring precise modulation of the receptor's activity. Through the study of OR13C9 inhibitors, scientists aim to gain deeper insights into the receptor's role in various biological systems and to explore how its activity can be modulated to influence different cellular processes.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pertussis Toxin (islet-activating protein)

70323-44-3sc-200837
50 µg
$451.00
3
(1)

Inactivates G(i/o) proteins, possibly preventing OR13C9 from initiating its signaling cascade.

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$137.00
$512.00
7
(1)

Inhibits Cdc42 GTPase, possibly affecting cytoskeletal arrangements necessary for OR13C9 function.

Gö 6983

133053-19-7sc-203432
sc-203432A
sc-203432B
1 mg
5 mg
10 mg
$105.00
$299.00
$474.00
15
(1)

Inhibits protein kinase C, which could disrupt downstream signaling of OR13C9.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

Inhibits Rho-associated kinase, potentially affecting GPCR trafficking and signaling including that of OR13C9.

BAPTA/AM

126150-97-8sc-202488
sc-202488A
25 mg
100 mg
$138.00
$458.00
61
(2)

Chelates intracellular calcium, which may interfere with calcium-dependent processes of OR13C9.

Suramin sodium

129-46-4sc-507209
sc-507209F
sc-507209A
sc-507209B
sc-507209C
sc-507209D
sc-507209E
50 mg
100 mg
250 mg
1 g
10 g
25 g
50 g
$152.00
$214.00
$728.00
$2601.00
$10965.00
$21838.00
$41096.00
5
(1)

Blocks purinergic receptors, which may alter ATP-dependent signaling pathways associated with OR13C9.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Inhibits PI3K, which could affect downstream signaling affecting OR13C9 activity.

Clozapine

5786-21-0sc-200402
sc-200402A
sc-200402B
sc-200402C
50 mg
500 mg
5 g
10 g
$69.00
$364.00
$2500.00
$4100.00
11
(1)

Antagonist of various neurotransmitter receptors, potentially modifying signaling pathways that OR13C9 engages in.